Risk factors
HeartSciences (HSCS) risk factors
Item 1A of every HeartSciences Inc. 10-K on file, and what changed from one year to the next.
- FY2026 10-K risk factors
80 risks, 13 new, 12 dropped, 11 reworded since the prior year. AI-ECG performance, FDA and EU AI regulation now dominate product commercialization risks.
Filed Jul 23, 2026 - FY2025 10-K risk factors
79 risks. HeartSciences is a development-stage medical device company heavily dependent on FDA approval and commercialization of its MyoVista wavECG and cloud platform. The company faces severe liquidity issues, Nasdaq delisting risks due to low stock price and stockholders equity, and internal control weaknesses. Operations rely on third-party suppliers, cloud providers, and clinical trial partners without current third-party payor reimbursement.
Filed Jul 24, 2025